학술논문
Six-month patient-reported outcome (PRO) results from AQUARiUS, a prospective, observational, multicenter phase 4 study in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone acetate plus prednisone (AAP) or enzalutamide (ENZ).
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15277755